The use of disease-modifying agents among multiple sclerosis patients enrolled in medicare from 1995 to 2002 and the impact of medicare part D: Analysis of claims data from the medicare current beneficiary survey

Clinical Therapeutics

Volumn 28, Issue 1, 2006, Pages 140-145

  Lundy, Jason ^a   Craig, Benjamin M ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Disease modifying agents; Medicare; Multiple sclerosis; Part D

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ARTICLE; BILLING AND CLAIMS; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MEDICARE; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PRESCRIPTION; PREVALENCE;

ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MEDICARE; MIDDLE AGED; MULTIPLE SCLEROSIS; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 32844472328     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.01.003     Document Type: Article

References (15)

1. Henriksson F., Fredrikson S., Masterman T., and Jonsson B. Costs, quality of life and disease severity in multiple sclerosis: A cross-sectional study in Sweden Eur J Neurol. 8 2001 27 35
2. Amato M.P., Battaglia M.A., and Caputo D. The costs of multiple sclerosis: A cross-sectional, multicenter cost-ofillness study in Italy J Neurol. 249 2002 152 163
3. New research: Recently funded projects Fall 2005 December 6, 2005
4. Medicare replacement drug demonstration December 6, 2005
5. Medicare Prescription Drug, Improvement and Modernization Act of 2003, Pub L No. 108-173.
6. Just the facts: 2005-2006 December 7, 2005
7. Whetten-Goldstein K., Sloan F.A., Goldstein L.B., and Kulas E.D. A comprehensive assessment of the cost of multiple sclerosis in the United States Mult Scler 4 1998 419 425
8. Pope G.C., Urato C.J., and Kulas E.D. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations Neurology 58 2002 37 43
9. Phillips C. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment CNS Drugs. 18 2004 561 574
10. Kobelt G., Lindgren P., Smala A., Jonsson B. German Cost of MS Study Group Costs and Quality of Life in Multiple Sclerosis: A Cross-Sectional Observational Study in Germany Working Paper Series in Economics and Finance, No. 399 2000 Stockholm School of Economics Stockholm, Sweden
11. Leibowitz A., Manning W.G., and Newhouse J.P. The demand for prescription drugs as a function of cost-sharing Soc Sci Med. 21 1985 1063 1069
12. Soumerai S.B., Avorn J., Ross-Degnan D., and Gortmaker S. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity N Engl J Med. 317 1987 550 556
13. Soumerai S.B., McLaughlin T.J., and Ross-Degnan D. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia N Engl J Med. 331 1994 650 655
14. International Classification of Diseases, Ninth Revision, Clinical Modification 6th ed. 2003 US Dept of Health and Human Services, Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services Washington DC
15. Survey overview December 21, 2005